Vertex cystic fibrosis combo succeeds in key late-stage trials
Tuesday, June 24, 2014 - 11:50
in Health & Medicine
(Reuters) - A combination of Vertex Pharmaceuticals Inc's VRTX.O cystic fibrosis drugs succeeded in improving lung function in a pair of closely watched late-stage trials, likely offering a potential new treatment for thousands more patients with the rare lung disease and sending Vertex shares soaring.